A Proton Pump Inhibitor, Lansoprazole, Ameliorates Asthma Symptoms in Asthmatic Patients with Gastroesophageal Reflux Disease
|
|
- Barbra O’Connor’
- 6 years ago
- Views:
Transcription
1 Tohoku J. Exp. Med., Proton 2006, Pump 209, Inhibitor, Lansoprazole, in Asthma Symptoms with GERD 181 A Proton Pump Inhibitor, Lansoprazole, Ameliorates Asthma Symptoms in Asthmatic Patients with Gastroesophageal Reflux Disease YASUO SHIMIZU, KUNIO DOBASHI, 1 SETSUO KOBAYASHI, 2 ICHIRO OHKI, 2 MASAHIKO TOKUSHIMA, 2 MOTOYASU KUSANO, OSAMU KAWAMURA, YASUYUKI SHIMOYAMA, MITSUYOSHI UTSUGI, NORIAKI SUNAGA, TAMOTSU ISHIZUKA and MASATOMO MORI Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Gunma, Japan, 1 Gunma University Faculty of Health Science, Gunma, Japan, and 2 Maebashi North Hospital, Gunma, Japan SHIMIZU, Y., DOBASHI, K., KOBAYASHI, S., OHKI, I., TOKUSHIMA, M., KUSANO, M., KAWAMURA, O., SHIMOYAMA, Y., UTSUGI, M., SUNAGA, N., ISHIZUKA, T. and MORI, M. A Proton Pump Inhibitor, Lansoprazole, Ameliorates Asthma Symptoms in Asthmatic Patients with Gastroesophageal Reflux Disease. Tohoku J. Exp. Med., 2006, 209 (3), Aspiration of acid to the airway causes airway inflammation, and acid stress to the airway caused by gastroesophageal reflux disease (GERD) has been known as a potential mechanism of deteriorated asthma symptoms. However, the efficacy of the acid suppressive drugs, H 2 -receptor blockers (H 2 blocker) and proton pump inhibitors, on asthma symptoms and pulmonary functions remains controversial. We therefore designed the randomized prospective study to determine the efficacy of an H 2 blocker (roxatidine, 150 mg/day) and a proton pump inhibitor (lansoprazole, 30 mg/day) on asthma symptoms of 30 asthmatic patients with GERD. These patients were divided in the two groups (15 patients for each group) and treated with either roxatidine or lansoprazole. The diagnosis of GERD was established by the method of Los Angeles classification including mucosal minimum change of Grade M and questionnaire for the diagnosis of reflux disease (QUEST) score. The efficacy of acid suppressive drugs was evaluated by peak expiratory flow (PEF), asthma control questionnaire (ACQ) that evaluates the improvement of asthma symptoms, and forced expiratory volume in 1 second (FEV 1.0 ). Lansoprazole, but not roxatidine, significantly improved PEF and ACQ scores (p < 0.05) with the improved QUEST scores. However, these acid suppressive drugs did not change the pulmonary function of FEV 1.0 in asthmatic patients. In conclusion, treatment with a proton pump inhibitor, lansoprazole, appears to be useful in improvement of asthma symptoms in asthmatic patients with GERD. asthma; gastroesophageal reflux disease; proton pump inhibitor; H 2 - receptor blocker 2006 Tohoku University Medical Press Received March 6, 2006; revision accepted for publication April 10, Correspondence: Yasuo Shimizu, M.D., Ph.D., Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Showa-machi, Maebashi, Gunma , Japan. yasuos@med.gunma-u.ac.jp 181
2 182 Y. Shimizu et al. Potential mechanisms to explain the relationship between asthma and gastroesophageal reflux disease (GERD) include microaspiration of acid into the airway (Tuchman et al. 1984), vagal reflex response to acid aspiration (Altschuler 2001), neuroinflammatory reflex to acid stimuliinduced synergistic interactions between esophageal nociceptors and airway sensory nerves (Caning and Mazzone 2003), and airway ph deviation-induced inflammatory cell activation in the airway (Ricciardolo et al. 2004). These mechanisms imply that the elimination of acid stress from the airway would contribute to an improvement in patients with asthma. There have been many studies dealing with asthma outcome and medical anti-reflux therapy. Field and Sutherland (1998) reviewed the previously published data on medical anti-reflux therapy with H 2 -receptor blockers (H 2 blockers), cimetidine (Goodall et al. 1981; Larrain et al. 1991) and ranitidine (Harper et al. 1987; Nagel et al. 1988; Ekstrom et al. 1989; Gustaffson et al. 1992), and with a proton pump inhibitor (PPI) omeprazole (Ford et al. 1994; Meier et al. 1994; Harding et al. 1996; Teichtahl et al. 1996), showing that asthma symptoms were improved. Kiljander (2003) suggested that, in the management of GERD-related asthma, PPIs other than omeprazole should be used at double the standard dose. A PPI, rabeprazole, was proven to inhibit gastric acid secretion (Hongo et al. 1998). Recently, rabeprazole at 20 mg b.i.d. (double the standard dose) was shown to improve the morning and evening peak expiratory flow rates (PEF) in asthmatic patients (Tsugeno et al. 2003). Lansoprazole, another PPI, has also been shown to be effective for the treatment of GERD (Chiba 1997; Malagelada 2004). Although Kiljander (2003) recommended that lansoprazole be given at double the standard dose (30 mg b.i.d.) in asthmatic patients, there have been no studies of the asthma symptoms changes and PEF change in various grades of asthma patients with GERD examined by endoscopy. Field and Sutherland (1998) showed that treatment with an H 2 blocker (cimetidine or ranitidine) improved asthma symptoms. Although roxatidine is an H 2 blocker and is useful for the treatment of GERD (Friedrich 1996; Hatlebakk and Berstad 1996), there have been no studies of the effect of roxatidine in asthmatic patients with GERD. The present study was designed to determine the efficacy of an H 2 blocker (roxatidine, 150 mg/ day) and a PPI (lansoprazole, 30 mg/day) on asthma symptoms and the pulmonary function in asthmatic patients with GERD. In this study, we first examined the presence of GERD in asthmatic patients on endoscopic examination using the Los Angeles classification (LA classification) (Armstrong et al. 1996) with the addition of Grade M (Hoshihara and Hashimoto 2000), defined as minimal change of the esophageal mucosa to observe acid exposure for esophageal mucosa precisely, and also presence of GERD was evaluated by questionnaire for the diagnosis of reflux disease (QUEST) (Carlsson et al. 1998). We then examined the changes in the QUEST scores to evaluate GERD symptoms, morning PEF and forced expiratory volume in 1 second (FEV 1.0 ) to evaluate asthma status objectively, and asthma symptoms using asthma control questionnaire (ACQ) (Juniper et al. 1999) in the two groups. METHODS AND STUDY DESIGN Subjects The diagnosis of asthma was based on the American Thoracic Society s definition of asthma (American Thoracic Society 1962). Asthmatic patients were excluded if they were pregnant or lactating, under 16 years of age, smokers, mentally incompetent, or had liver, kidney, or other severe diseases. Patients with a history of esophageal, gastric, or duodenal surgery were also excluded, as were patients with a history of druginduced allergy and those being treated with an angiotensin-converting enzyme (ACE) inhibitor, a muscarine receptor antagonist or acid suppressive drugs. Asthma medications were given according to the levels of the severity defined by Global strategy for asthma treatment and prevention, Global initiative for asthma (GINA) (National Institute of Health, National Heart, Lung, and Blood Institute 2003). The levels of asthma severity in GINA are described in the following section. Asthma medications were not changed during the study period.
3 Proton Pump Inhibitor, Lansoprazole, in Asthma Symptoms with GERD 183 Grading of asthma severity and the asthma treatment score Asthma severity was graded using GINA. GINA classifies asthma status into 3 general levels, mild, moderate and severe, with the mild level being further divided into two levels. Briefly, level 1 is called the mild intermittent type with asthma symptoms appearing less than once a week, and the PEF is over 80% of predicted flow. Level 2 is called the mild continuous type with asthma symptoms appearing more than once a week, though not every day, and the PEF is over 80% of predicted flow. Level 3 represents the moderate continuous type with asthma symptoms appearing every day, and the PEF is from 60% to 80% of predicted flow. Level 4 represents the severe continuous type with asthma symptoms worsening despite asthma treatment, and the PEF is less than 60% of predicted flow. In present study, the changes in asthma symptoms were assessed using the ACQ (Juniper et al. 1999). The ACQ has been used in the previous studies (Vollmer et al. 1999; Rosenhall et al. 2003), and composes of 6 questions for patients and 1 question for the doctors, which are easy to answer. The ACQ has been proven to correlate with asthma control. Each question was about the frequency of woken by asthma during night, or morning, limitation of activities, shortness of breath, wheeze, puffs of short-acting bronchodilator and levels of FEV 1.0. Patients answer the questions according to their symptoms levels 0 (never) to 6 (very severe). FEV 1.0 were graded 0 (> 95% predicted) to 6 (< 50% predicted). To evaluate airflow limitation, PEF was measured using a Mini Wright PEF meter (Health Scan Products Inc., Cedar Grove, NJ, USA) using the American Thoracic Society (ATS) scale. The patients measured PEF every morning. The two-week means of PEF before treatment and the two-week means before the end of the study (the seventh and eighth weeks) were used for evaluation. Pulmonary function of FEV 1.0 was measured by CHESTAC 55V (CHEST MI, Tokyo). Evaluation of GERD The diagnosis of GERD was established by endoscopic examination using the LA classification (Armstrong et al. 1996) of Grade A to D with minimum change of Grade M and no apparent mucosal change of Grade N (Hoshihara and Hashimoto 2000). Grade M (minimal change) is defined by the presence of prominent erythema without clear demarcation or whitish cloudiness of the lower esophageal mucosa obscuring the longitudinal blood vessels. The LA classification defines the changes of a clearly esophageal mucosal break as an area of slough or erythema demarcated from adjacent normal-appearing mucosa. It has been reported that there is a large number of patients with GERD who are below Grade A, and are labeled as Grades N and M (Hoshihara et al. 2000). To observe acid exposure for esophageal mucosa precisely, we use the LA classification with grade M and N. In our randomized study, the LA classification was determined before starting H 2 blocker or PPI treatment. Diagnosis of GERD was made by four endoscopists (Shimoyama et al. 2005). A QUEST score, which has been proven to be useful in the assessment of GERD, was used to assess GERD symptoms (Carlsson et al. 1998; Tsugeno et al. 2003). A QUEST score 4 was diagnostic of GERD. Randomized study design The design of the randomized study is shown in Table 1. Enrolled patients were outpatients under asthma treatment by Maebashi North Hospital and Gunma University Hospital, or visited Maebashi North Hospital and Gunma University Hospital for the reason of difficult to control asthma from another hospital. Thirty asthma patients agreed to participate in the two-group, randomized prospective study of the effects of acid suppression on asthma symptoms using an H 2 blocker and a PPI. Six patients were enrolled in Maebashi North Hospital, and twenty-four patients were enrolled in Gunma University Hospital. Patients were randomly and blindly assigned to oral treatment with either the H 2 blocker roxatidine (150 mg/day) or the PPI lansoprazole (30 mg/day) for 2 months. The dose of 30 mg lansoplazole was the same dose as recommend for GERD control dose by previous report (Kiljander 2003). They underwent endoscopic examination, and the QUEST score was determined. Patients enrolled in the randomized study had GERD symptoms (QUEST 4) and/or an endoscopic examination showing Grade M. The changes in the QUEST score, the asthma symptom score, PEF, FEV 1.0, and nonspecific IgE assayed by radio immunosorbent test (RIST) (normal upper limit, 250 IU/ml) were evaluated before and after two months of therapy. Patients recorded PEF for two weeks prior to starting the medication, and then recorded PEF every day after starting. The asthma treatment regimen was not changed during the first two months of the study period. To check for any adverse effects of acid suppressive treatment, the white blood count (WBC), the red blood cell count (RBC), aspartate
4 184 Y. Shimizu et al. TABLE 1. Randomized study protocol and QUEST score in H 2 blocker (Roxatidine) group and PPI group (Lansoprazole) before starting treatment. The difference between two groups in QUEST score, PEF and ACQ were tested using 2 2 Chi-square test with Yates s test applied to adjust data where the sample number was < 10. Quest score was not different between groups before starting study. ACQ, asthma control questionnaire. aminotransferase (AST), alanine aminotranseferase (ALT), lactate dehydrogenase isozyme (LDH), blood urea nitrogen (BUN), Cr, Na, K and Cl, were measured before and after the study. The study was conducted according to the guidelines of the Declaration of Helsinki, and all patients gave written informed consent before enrollment in the study. Approval for this study was given by the Human Research Committee of Maebashi North Hospital and Gunma University Institution. This study was started from June 1, 1998 in Maebashi North Hospital, and started from August 1, 2000 in Gunma University Hospital. Statistical analysis All values are shown as means ± S.D. The difference between two groups were tested using 2 2 Chisquare test with Yates s test applied to adjust data where the sample number was < 10. Changes in the PEF and asthma symptom score before and after drug administration were tested using the Wilcoxon t-test. Statistical significance was set at p < RESULTS The patient characteristics for each group are shown in Table 2; no differences in age, gender, LA grades and asthma grades were observed between the two groups. Enrolled asthma patients with grade N had GERD symptoms evaluated by QUEST score 4. The randomized study of roxatidine and lansoprazole showed that before treatment, a QUEST score 4 was obtained in 10/15 (66.7%) roxatidine-treated patients and in 11/15 (73.3%) lansoprazole-treated patients (p = ns, Table 1). The pre-treatment QUEST score was 8.1 ± 4.9 (mean ± S.D.) in the roxatidine-treated group and 8.3 ± 4.9 (mean ± S.D.) in the lansoprazoletreated group (Fig. 1). After treatment, the QUEST score was 4 ± 3.6 (mean ± S.D.) in the roxatidine-treated group and 2.4 ± 2.8 (mean ± S.D.) in the lansoprazole-treated group. In both groups, the QUEST scores showed significant improvement with treatment (p < 0.05). Before treatment, PEF was ± (mean ± S.D.) in the roxatidine-treated group and ± (mean ± S.D.) in the lansoprazole-treated group (Fig. 2). After treatment, the PEF was ± (mean ± S.D.) in the roxatidine-treated group and ± (mean ± S.D.) in the lansoprazole-treated group. Two months of lansoprazole therapy significantly improved PEF (p < 0.05), but roxatidine therapy did not significantly improve PEF. Before the treatment, the PEF was not significantly different between the roxatidine-
5 Proton Pump Inhibitor, Lansoprazole, in Asthma Symptoms with GERD 185 TABLE 2. Patients characters. Patients characters between groups in age, gender (M/F), LA grades and asthma grades were not significantly different. The difference between two groups were tested using 2 2 Chi-square test with Yates s test applied to adjust data where the sample number was < 10. Roxatidine (H 2 blocker) group Lansoplazole (PPI) group Age (mean ± S.D.) 59 ± ± 11 M/F (pt number) 7/8 6/9 LA Grade (number of patients) N 3 2 M 4 5 A 6 7 B 1 1 C 1 0 D 0 0 Asthma grades (number of patients) Step Step Step Step Fig. 1. QUEST score changes before and after roxatidine and lansoprazole treatment in asthmatic patients. Statistically significant differences before and after treatment are expressed by * p < 0.05.
6 186 Y. Shimizu et al. Fig. 2. PEF changes before and after roxatidine and lansoprazole treatment in asthmatic patients. Statistically significant differences before and after treatment are expressed by * p < TABLE 3. Changes of FEV 1.0, IgE levels, asthma symptoms evaluated by ACQ. Changes in the PEF and asthma symptom score before and after drug administration were tested using the Wilcoxon t-test. Statistical significance was set at p < Roxatidine (H 2 blocker) group Lansoplazole (PPI) group FEV 1.0 before (ml) 1,839.7 ± ,993.3 ± FEV 1.0 after (ml) 2,003.3 ± ,057.4 ± IgE before (IU/ml) ± ± IgE after (IU/ml) ± ± ACQ before (mean ± S.D.) 12.3 ± ± 4.2 ACQ after (mean ± S.D.) 9.0 ± ± 4.2 * treated and lansoprazole-treated groups. ACQ scores were improved in lansoprazole group, and FEV 1.0 and IgE were not affected by roxatidine or lansoprazole treatment (Table 3). The asthma treatment score was decreased in the lansoprazole-treated group (p < 0.05), but the score was not decreased in the roxatidine-treated group. Blood test results, including WBC, RBC, AST, ALT, LDH, BUN, Cr, Na, K and Cl were not affected by either treatment, and no adverse effects were noted with either treatment. DISCUSSION We tested whether acid suppressive medication contributed to an improvement of asthma. GERD symptoms, evaluated by the QUEST score, were ameliorated in both the roxatidine-treated and lansoprazole-treated patients (Fig. 1), but PEF
7 Proton Pump Inhibitor, Lansoprazole, in Asthma Symptoms with GERD 187 and asthma symptoms were improved only in the lansoprazole-treated group (Fig. 2, Table 3). Both roxatidine and lansoprazole have been shown to improve reflux symptoms in patients with GERD by more than 90% (Friedrich et al. 1996; Malagelada et al. 2004). However, endoscopic healing rates do not necessarily correspond with symptom improvement rates (Friedrich et al. 1996). PPIs have a greater effect on acid suppression than H 2 blockers and are highly effective for acute healing of erosive esophagitis; in fact, they are the only class of drug that minimizes relapse of esophagitis (Chiba 1997). These differences may be responsible for the different results obtained in the roxatidine-treated and lansoprazole-treated groups with respect to PEF improvement, asthma symptom improvement, although both drugs improved GERD symptoms evaluated by QUEST. Changing from an H 2 blocker to a PPI has been shown to increase PEF (Tsugeno et al. 2003), which is in agreement with our results. These indicate that the PPI is superior to the H 2 blocker for treating asthmatic patients with GERD. The present study showed lansoprazole increased PEF and improved asthma symptoms, but the degree was slightly increasing about 20 L/min. This implies clinical relevance of PPI in increase of PEF is not so much in dilatation of bronchus, and PPI treatment contributes to asthma symptoms improvement on asthma patients with GERD. Consistent with a previous report (Field and Sutherland 1998), the present study has shown that FEV 1.0 was not affected in asthmatic patients treated with a H 2 blocker or a PPI. Kiljander et al. (2003) suggested that FEV 1.0 was not improved in asthmatic patients because they had good asthma control before PPI treatment, and relatively severe GERD was due to insufficient PPI treatment. However, in the present study, the severity of asthma was variable, and GERD severity was also variable (Table 2). As in previous reports, we found that PPI treatment did not affect FEV 1.0 (Kiljander 2003). Recently, large multi-center trial evaluating the effects of esomeprazole (40 mg b.i.d) on asthma had been completed, showing significant improvement in asthma symptom scores and PEF only in patients with GERD and nocturnal respiratory symptoms (Kiljander et al. 2006). Legget et al. (2005) have reported that in patients with difficult-to-control asthma, GERD was common, but the identification and treatment of GERD did not appear to improve asthma control. Boeree et al. (1998) have reported that high-dose PPI treatment had no effect in patients with severe airway hyper-responsiveness and symptomatic GERD. The severity of GERD and the severity of asthma seem to be two important factors when evaluating the effects of acid suppressive medication on asthma in asthmatic patients with GERD. Elevation of IgE indicates presence of atopy or allergy to drugs (Gina 2003). IgE levels in present study were unchanged in both groups of patients treatred with roxatidine or lansoprazole, suggesting that acid suppressive drugs did not cause IgE-mediated drug allergy in asthma patients in present study. In the enrolled asthma patients, IgE levels were not elevated, unlike atopic asthma with IgE elevation. A recent report has shown that gastric acidsuppressive therapy was associated with an increased risk of community-acquired pneumonia (Laheij et al. 2004). However, the treatment duration and the dosage of PPI therapy in asthmatic patients with GERD still need to be addressed. Previous studies have recommended the highdose therapy for 2 to 3 months (Harding and Sontag 2000; Harmanci et al. 2001). Exogenous airway acidification by GERD or acid fogs were important factors in the deterioration of asthma, contributed to a decrease in ph with airway inflammation, and altered immune cell function. Taken together, the airway ph homeostasis could be a new target for therapy (Ricciardolo et al. 2004). Thus, PPI therapy is needed to avoid airway acidification in patients with asthma, but the duration and dosage of PPI treatment remains to be determined keeping an airway homeostasis without increase in the risk of pneumonia in asthma patients with GERD. In conclusion, to effectively treat asthmatic patients with GERD, we need to elucidate the pathogenesis of asthma with GERD, the rates of the various asthma outcomes with PPI therapy,
8 188 Y. Shimizu et al. and how to use intermittent PPI therapy. Further research will be needed to determine the place of PPI in asthma treatment guideline. Acknowledgments This study was not supported by any grants. Shimizu, Y. and Dobashi, K. designed the study, and treated asthma patients, and summarized the data. Kobayashi, S. and Mori, M. participated in designing the study. Ohki, I., Kusano, M., Kawamura, O. and Shimoyama, Y. diagnosed GERD. Tokushima, M., Sunaga, N., Ishizuka, T. and Utsugi, M. contributed diagnosis of asthma, and treated asthma patients. References Altschuler, S.M. (2001) Laryngeal and respiratory protective reflexes. Am. J. Med., 111, 90S-94S. American Thoracic Society (1962) Definition and classification of chronic bronchitis, asthma and pulmonary emphysema. Am. Rev. Respir. Dis., 85, Armstrong, D., Bennett, J.R., Blum, A.L., Dent, J., De Dombal, F.T., Galmiche, J.P., Lundell, L., Margulies, M., Richter, J.E., Spechler, S.J., Tygat, G.N. & Wallin, L. (1996) The endoscopic assessment of esophagitis: a progress report on observer agreement. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology, 111, Boeree, M.J., Peters, F.T., Postma, D.S. & Kleibeuker, J.H. (1998) No effects of high-dose omeprazole in patients with severe airway hyperresponsiveness and (a) symptomatic gastro-oesophageal reflux. Eur. Respir. J., 11, Canning, B. & Mazzone, S.B. (2003) Reflex mechanisms in gastroesophageal reflux disease and asthma. Am. J. Med., 115, 45S-48S. Carlsson, R., Dent, J., Bolling-Sternevald, F., Johnsson, F., Johnsson, F., Junghard, O., Lauritsen, K., Riley, S. & Lundell, L. (1998) The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand. J. Gastroenterol., 33, Chiba, N. (1997) Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview. Can. J. Gastroenterol., 11, 66B-73B. Ekstrom, T., Lindgren, B.R. & Tibbling, L. (1989) Effects of ranitidine treatment on patients with asthma and a history of gastro-oesophageal reflux: a double blind crossover study. Thorax, 44, Field, S.K. & Sutherland, L.R. (1998) Does medical antireflux therapy improve asthma in asthmatics with gastroesophageal reflux?: a critical review of the literature. Chest, 114, Ford, G.A., Oliver, P.S., Prior, J.S. & Butland, R.J. (1994) Omeprazole in the treatment of asthmatics with nocturnal symptoms and gastro-oesophageal reflux: a placebocontrolled cross-over study. Postgrad Med. J., 70, Friedrich, P., Botzler, R., Mayershofer, R. & Kriech, W. (1996) Roxatidine acetate in therapy of reflux esophagitis. Fortschr. Med., 114, Goodall, R.J., Cooper, D.N., Bernstein, A. & Temple, J.G. (1981) Relationship between asthma and gastro-oesophageal reflux. Thorax, 36, Gustaffson, P.M., Kjellman, N.J. & Tibbling, L. (1992) A trial of ranitidine in asthmatic children and adolescents with or without pathological gastro-oesophageal reflux. Eur. Respir. J., 5, Harding, S.M., Richter, J.E., Guzzo, M.R & Schan, C.A. (1996) Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcome. Am. J. Med., 100, Harding, S.M. & Sontag, S.J. (2000) Asthma and gastroesophageal reflux. Am. J. Gastroenterol., 95, S23-S32. Harmanci, E., Entok, E., Metintas, M. & Vardareli, E. (2001) Gastroesophageal reflux in the patients with asthma. Allergol. Immunopathol. (Madr)., 29, Harper, P.C., Bergner, A. & Kaye, M.D. (1987) Antireflux treatment for asthma. Improvement in patients with associated gastroesophageal reflux. Arch. Intern. Med., 147, Hatlebakk, J.G. & Berstad, A. (1996) Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. Clin. Pharmacokinet., 31, Hongo, M., Kimpara, T., Moriyama, S., Ohara, S., Sone, S., Tamura, T., Asaki, S. & Toyota, T. (1998) Effect of rabeprazole (E3810), a novel proton pump inhibitor, on intragastric ph in healthy volunteers. Tohoku J. Exp. Med., 186, Hoshihara, Y. & Hashimoto, M. (2000) Endoscopic classification of reflux esophagitis. Nippon Rinsho., 58, Juniper, E.F., O Byrne, P.M., Guyatt, G.H. & Ferrie, P.J. (1999) Development and validation of a questionnaire to measure asthma control. Eur. Respir. J., 14, Kiljander, T.O. (2003) The role of proton pump inhibitors in the management of gastroesophageal reflux disease-related asthma and chronic cough. Am. J. Med., 115, 65S-71S. Kiljander, T.O., Harding, S.M., Field, S.K., Stein, M.R., Nelson, H.S., Ekelund, J., Illueca, M., Beckman, O. & Sostek, M.B. (2006) Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial. Am. J. Respir. Crit. Care Med., 173, Laheij, R.J., Sturkenboom, M.C., Hassing, R.J. & Dieleman, J. (2004) Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA, 292, Larrain, A., Carrascos, E., Galleguillos, F. & Sepulveda, R. (1991) Medical and surgical treatment of nonallergic asthma associated with gastroesophageal reflux. Chest, 99, Leggett, J.J., Johnston, B.T., Mills, M. & Gamble, J. (2005) Prevalence of gastroesophageal reflux in difficult asthma: relationship to asthma outcome. Chest, 127, Malagelada, J.R. (2004) Supra-oesophageal manifestations of gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther., 19, Meier, J.H., McNally, P.R., Punja, M. & Freeman, S.R. (1994) Does omeprazole (Prilosec) improve respiratory function in asthmatics with gastroesophageal reflux? A double-blind, placebo-controlled crossover study. Dig. Dis. Sci., 39, Nagel, R.A., Brown, P., Perks, W.H. & Wilson, R.S. (1988) Ambulatory ph monitoring of gastro-oesophageal reflux in morning dipper asthmatics. BMJ, 297, National Institute of Health, National Heart, Lung, and Blood institute (2003) Global strategy for asthma treatment and prevention, Global initiative for asthma (GINA). Ricciardolo, F.L., Gaston, B. & Hunt, J. (2004) Acid stress in the pathology of asthma. J. Allergy Clin. Immunol., 113,
9 Proton Pump Inhibitor, Lansoprazole, in Asthma Symptoms with GERD 189 Rosenhall, L., Elvstrand, A., Tilling, B., Vinge, I., Jemsby, P., Stahl, E., Jerre, F. & Bergqvist, P.B. (2003) One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma. Respir. Med., 97, Shimoyama, Y., Kusano, M., Sugimoto, S., Kawamura, O., Maeda, M., Minashi, K., Kuribayashi, S., Higuchi, T., Zai, H., Ino, K., Horikoshi, T., Moki, F., Sugiyama, T., Toki, M., Ohwada, T. & Mori, M. (2005) Diagnosis of gastroesophageal reflux disease using a new questionnaire. J. Gastroenterol. Hepatol., 20, Teichtahl, H., Kronborg, I.J., Yeomans, N.D. & Robbinson, P. (1996) Adult asthma and gastro-oesophageal reflux: the effects of omeprazole therapy on asthma. Aust. NZ J. Med., 26, Tsugeno, H., Mizuno, M., Fujiki, H., Okada, H., Okamoto, M., Hosaki, Y., Ashida, S., Mitsunobu, F., Tanizaki, Y. & Shiratori, Y. (2003) A proton-pump inhibitor, rabeprazole, improves ventilatory function in patients with asthma associated with gastroesophageal reflux. Scand. J. Gastroenterol., 38, Tuchman, D.N., Boyle, J.T., Pack, A.L., Scwartz, J., Kokonos, M., Spitzer, A.R. & Cohen, S. (1984) Comparison of airway responses following tracheal or esophageal acidification in the cat. Gastroenterology, 87, Vollmer, W.M., Markson, L.E., O conner, E., Sanocki, L.L., Fiterman, L., Berger, M. & Buist, A.S. (1999) Association of asthma control with health care utilization and quality of life. Am. J. Respir. Crit. Care Med., 160,
High Prevalence of Gastroesophageal Reflux Disease with Minimal Mucosal Change in Asthmatic Patients
Tohoku J. Exp. Med., 2006, Minimal 209, Mucosal 329-336Esophageal Change in Asthmatic Patients 329 High Prevalence of Gastroesophageal Reflux Disease with Minimal Mucosal Change in Asthmatic Patients YASUO
More informationEffect of Esomeprazole 40 mg Once or Twice Daily on Asthma A Randomized, Placebo-controlled Study
Effect of Esomeprazole 40 mg Once or Twice Daily on Asthma A Randomized, Placebo-controlled Study Toni O. Kiljander 1, Ola Junghard 2, Ola Beckman 2, and Tore Lind 2 1 Department of Respiratory Medicine,
More informationPrevalence of Gastro-oesophageal Reflux Disease in 'Difficult-to-Control' Asthma and Response to Medical Antireflux Therapy
Prevalence of Gastro-oesophageal Reflux Disease in 'Difficult-to-Control' Asthma and Response to Medical Antireflux Therapy Magdy M. Emara 1, 6, Mohamad A. Habeb 2, Mohamad A. Moharam 3, Mohmad Mosaad
More informationToni O. Kiljander, MD; Eija-Riitta M. Salomaa, MD; Eino K. Hietanen, MD; and Erkki O. Terho MD
Gastroesophageal Reflux in Asthmatics* A Double-Blind, Placebo-Controlled Crossover Study With Omeprazole Toni O. Kiljander, MD; Eija-Riitta M. Salomaa, MD; Eino K. Hietanen, MD; and Erkki O. Terho MD
More informationEffects of anti-reflux surgery on chronic cough and asthma in patients with gastro-oesophageal reflux disease
RESPIRATORY MEDICINE (2000) 94, 1166 1170 doi:10.1053/rmed.2000.0944, available online at http://www.idealibrary.com on Effects of anti-reflux surgery on chronic cough and asthma in patients with gastro-oesophageal
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our
More informationReview article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors
Aliment Pharmacol Ther 2003; 17 (Suppl. 1): 10 15. Review article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors J. G. HATLEBAKK Department of Medicine, Haukeland Sykehus,
More informationNo effects of high-dose omeprazole in patients with severe airway hyperresponsiveness and (a)symptomatic gastrooesophageal
Eur Respir J 1998; 11: 1070 1074 DOI: 10.1183/09031936.98.11051070 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1998 European Respiratory Journal ISSN 0903-1936 No effects of high-dose
More informationMaximizing Outcome of Extraesophageal Reflux Disease. (GERD) is often accompanied
...PRESENTATIONS... Maximizing Outcome of Extraesophageal Reflux Disease Based on a presentation by Peter J. Kahrilas, MD Presentation Summary Gastroesophageal reflux disease (GERD) accompanied by regurgitation
More informationReview article: pharmacology of esomeprazole and comparisons with omeprazole
Aliment Pharmacol Ther 2003; 17 (Suppl. 1): 5 9. Review article: pharmacology of esomeprazole and comparisons with omeprazole J. DENT Department of Gastroenterology, Hepatology and General Medicine, Royal
More informationCYP2C19-Proton Pump Inhibitors
CYP2C19-Proton Pump Inhibitors Cameron Thomas, Pharm.D. PGY2 Clinical Pharmacogenetics Resident St. Jude Children s Research Hospital February 1, 2018 Objectives: CYP2C19-PPI Implementation Review the
More informationGastroesophageal reflux disease (GERD) is a frequent presentation
Insight Into the Relationship Between Gastroesophageal Reflux Disease and Asthma Fehmi Ates, MD, and Michael F. Vaezi, MD, PhD, MSc (Epi) Dr Ates is an associate professor of medicine at Mersin University
More informationValidation of a Four-Graded Scale for Severity of Heartburn in Patients with Symptoms of Gastroesophageal Reflux Disease
Volume 11 Number 4 2008 VALUE IN HEALTH Validation of a Four-Graded Scale for Severity of Heartburn in Patients with Symptoms of Gastroesophageal Reflux Disease Ola Junghard, PhD, 1 Ingela Wiklund, PhD
More informationr(i The Fellowship of Postgraduate Medicine, 1994 report has described improvement of nocturnal asthma with omeprazole, a much more effective
Postgrad Med J (1994) 70, 350 354 r(i The Fellowship of Postgraduate Medicine, 1994 Omeprazole in the treatment of asthmatics with nocturnal symptoms and gastro-oesophageal reflux: a placebo-controlled
More informationStep-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide.
Step-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide. By: DR MOHD SHAMSUL AMRI Supervisor: Associate Professor Dr
More informationComparison of Clinical Findings with Symptom Assessment Systems (GerdQ and FSSG) for Functional Gastrointestinal Diseases
ORIGINAL PAPER Surg. Gastroenterol. Oncol. 2018;23(3):198-203 DOI: 10.21614/sgo-23-3-198 Comparison of Clinical Findings with Symptom Assessment Systems (GerdQ and FSSG) for Functional Gastrointestinal
More informationIntragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily a randomized, two-way crossover study
Aliment Pharmacol Ther 2005; 21: 963 967. doi: 10.1111/j.1365-2036.2005.02432.x Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily a randomized,
More informationA model of healing of Los Angeles grades C and D reflux oesophagitis: is there an optimal time of acid suppression for maximal healing?
Alimentary Pharmacology and Therapeutics A model of healing of Los Angeles grades C and D reflux oesophagitis: is there an optimal time of acid suppression for maximal healing? P. O. Katz*, D. A. Johnson
More informationSomkiat Wongtim Professor of Medicine Division of Respiratory Disease and Critical Care Chulalongkorn University
Somkiat Wongtim Professor of Medicine Division of Respiratory Disease and Critical Care Chulalongkorn University Asthma-related Comorbidities Comorbid conditions of the upper airways Rhinitis and Sinusitis
More informationGERD is a condition which develops when the reflux of stomach contents causes troublesome symptoms and/or complications
GERD is a condition which develops when the reflux of stomach contents causes troublesome symptoms and/or complications Esophageal Syndromes Extra - esophageal Syndromes Symptomatic Syndromes Typical reflux
More informationThe Prevalence of Gastroesophageal Reflux in Asthma Patients without Reflux Symptoms
The Prevalence of Gastroesophageal Reflux in Asthma Patients without Reflux Symptoms SUSAN M. HARDING, MELANY R. GUZZO, and JOEL E. RICHTER Division of Pulmonary, Allergy, and Critical Care Medicine, Department
More informationA comparison of global questions versus health status questionnaires as measures of the severity and impact of asthma
Eur Respir J 1999; 1: 591±596 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 1999 European Respiratory Journal ISSN 93-1936 A comparison of global questions versus health status questionnaires
More informationThe Impact of Gender on the Symptom Presentation and Life Quality of Patients with Erosive Esophagitis and Non-Erosive Reflux Disease
ARC Journal of Hepatology and Gastroenterology Volume 1, Issue 1, 2016, PP 3-8 www.arcjournals.org The Impact of Gender on the Symptom Presentation and Life Quality of Patients with Erosive Esophagitis
More informationEffects of omeprazole and cisapride treatment in Japanese asthmatics with reflux esophagitis
Allergology International (1997) 46: 167-172 Original Article Effects of omeprazole and cisapride treatment in Japanese asthmatics with reflux esophagitis Katsuya Fujimori,1 Eiichi Suzuki2 and Masaaki
More informationDual-Controller Asthma Therapy: Rationale and Clinical Benefits
B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach
More informationExtraesophageal presentations of gastroesophageal reflux disease: the case for aggressive diagnosis and treatment
JOEL E. RICHTER, MD Dr. Richter is chairman of the Department of Gastroenterology at the Cleveland Clinic Foundation, specializing in esophageal diseases with particular interest in GERD, achalasia, and
More informationNature and Science, 2009;7(5), ISSN ,
Study of Gastro Esophageal Reflux Disease in COD atients Adel M.Khattab*, Khaled Z. El-Karmouty**,Tamer M. Aly*, Asmaa H. Abdel Azeem* *Chest Department, Faculty of Medicine, Ain Shams University **Internal
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationOutline. Outline. Definition. Asthma, GERD and Laryngeal Pharyngeal Reflux (LPR) Definitions
Asthma, GERD and Laryngeal Pharyngeal Reflux (LPR) Richard F. Lockey, M.D. Division of Allergy and Immunology Department of Internal Medicine University of South Florida College of Medicine and James A.
More informationGASTRO-ESOPHAGEAL REFLUX DISEASE IN BRONCHIAL ASTHMA IS THERE AN ASSOCIATION?
GASTRO-ESOPHAGEAL REFLUX DISEASE IN BRONCHIAL ASTHMA IS THERE AN ASSOCIATION? *Gajanan S. Gaude and Jyothi Karanji Department of Pulmonary Medicine, J. N. Medical College, Belgaum -590010 *Author for correspondence
More informationCurrent reviews of allergy and clinical immunology (Supported by a grant from Astra Pharmaceuticals, Westborough, Mass)
Current reviews of allergy and clinical immunology (Supported by a grant from Astra Pharmaceuticals, Westborough, Mass) Series editor: Harold S. Nelson, MD Gastroesophageal reflux and asthma: Insight into
More informationDifferent gastoroesophageal reflux symptoms of middle-aged to elderly asthma and chronic obstructive pulmonary disease (COPD) patients
Original Article )JCBN Journal 0912-0009 1880-5086 the Kyoto, jcbn11-75 10.3164/jcbn.11-75 Original Society Japan of Article Clinical for Free Biochemistry Radical Research and Nutrition Japan Different
More informationHold the Wrap! There is so much more to be done!
Hold the Wrap! There is so much more to be done! (Well, a few things that can be done.) (Well, not all that much, really ) (But Blair has never killed anyone with a PPI!) Nicholas Shaheen, MD, MPH Center
More informationReview article: management of mild and severe gastro-oesophageal reflux disease
Aliment Pharmacol Ther 2003; 17 (Suppl. 2): 52 56. Review article: management of mild and severe gastro-oesophageal reflux disease G. N. J. TYTGAT Department of Gastroenterology and Hepatology, Academic
More informationHeartburn is a common symptom among adults in
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:553 563 Early Heartburn Relief With Proton Pump Inhibitors: A Systematic Review and Meta-analysis of Clinical Trials KENNETH R. MCQUAID*, and LOREN LAINE
More informationUnmet Needs in the Management of Gastroesophageal Reflux Disease
Unmet Needs in the Management of Gastroesophageal Reflux Disease Ronnie Fass MD Professor of Medicine Case Western Reserve University Chairman, Division of Gastroenterology and Hepatology Director, Esophageal
More informationT here has been considerable interest during
701 REVIEW Gastro-oesophageal reflux and bronchial asthma: current status and future directions J L Mathew, M Singh, S K Mittal... In recent years there have been several reports suggesting an association
More informationTreatment Options for Complicated/Severe Asthma. Henry J. Kanarek, MD Kanarek Allergy Asthma Immunology
Treatment Options for Complicated/Severe Asthma Henry J. Kanarek, MD Kanarek Allergy Asthma Immunology www.kallergy.com 913-451-8555 Asthma Epidemiology World Health Organization, Asthma is one of the
More informationSupplementary Online Content
Supplementary Online Content Regan EA, Lynch DA, Curran-Everett D, et al; Genetic Epidemiology of COPD (COPDGene) Investigators. Clinical and radiologic disease in smokers with normal spirometry. Published
More informationCase-Compare Impact Report
Case-Compare Impact Report October 8, 20 For CME Activity: Developed through an independent educational grant from Genentech: Moderate to Severe Persistent Asthma: A Case-Based Panel Discussion (March
More informationLife-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton
Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary
More informationORIGINAL ARTICLE. Abstract. Introduction. Masaki Miyamoto 1, Noriaki Manabe 2 and Ken Haruma 2
ORIGINAL ARTICLE Efficacy of the Addition of Prokinetics for Proton Pump Inhibitor (PPI) Resistant Non-erosive Reflux Disease (NERD) Patients: Significance of Frequency Scale for the Symptom of GERD (FSSG)
More informationGERD: 2014 Dilemmas and Solutions. Ronnie Fass MD, FACP Professor of Medicine Case Western Reserve University
GERD: 2014 Dilemmas and Solutions Ronnie Fass MD, FACP Professor of Medicine Case Western Reserve University How to Maximize Your PPI Treatment? Improve compliance and adherance Fass R. Am J Gastroenterol.
More informationRpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives
Esomeprazole 20mg Name, Restriction, Manner of esomeprazole 20 mg enteric tablet, 30 (8886Q) (029W) Gastric ulcer Peptic ulcer Treatment Phase: Initial treatment The therapy must be for initial treatment
More informationHCT Medical Policy. Bronchial Thermoplasty. Policy # HCT113 Current Effective Date: 05/24/2016. Policy Statement. Overview
HCT Medical Policy Bronchial Thermoplasty Policy # HCT113 Current Effective Date: 05/24/2016 Medical Policies are developed by HealthyCT to assist in administering plan benefits and constitute neither
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: esophageal_ph_monitoring 4/2011 5/2017 5/2018 5/2017 Description of Procedure or Service Acid reflux is the
More informationThe effect of anti-reflux treatment on subjective voice measurements of patients with laryngopharyngeal reflux
The Journal of Laryngology & Otology (2013), 127, 590 594. JLO (1984) Limited, 2013 doi:10.1017/s0022215113000832 MAIN ARTICLE The effect of anti-reflux treatment on subjective voice measurements of patients
More informationORIGINAL ARTICLE. Proximal Reflux as a Cause of Adult-Onset Asthma
ORIGINAL ARTICLE Proximal Reflux as a Cause of Adult-Onset Asthma The Case for Hypopharyngeal Impedance Testing to Improve the Sensitivity of Diagnosis Yoshihiro Komatsu, MD; Toshitaka Hoppo, MD, PhD;
More informationCommittee Approval Date: October 14, 2014 Next Review Date: October 2015
Medication Policy Manual Topic: esomeprazole-containing medications: - Nexium - Vimovo - esomeprazole strontium Policy No: dru039 Date of Origin: May 2001 Committee Approval Date: October 14, 2014 Next
More informationJournal of the COPD Foundation
221 Azithromycin in COPD and GERD Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation Original Research Azithromycin and COPD Exacerbations in the Presence or Absence of Symptoms or
More informationGastro-oesophageal reflux related cough and its response to laparoscopic fundoplication
Thorax 1998;53:963 968 963 Departments of Medicine and Surgery, McMaster University, St Joseph s Hospital, Hamilton, Ontario, Canada L8N 4A6 C J Allen M Anvari Correspondence to: Dr C Allen. Received 10
More informationEosinophilic Esophagitis (EoE)
Eosinophilic Esophagitis (EoE) 01.06.2016 EoE: immune-mediated disorder food or environmental antigens => Th2 inflammatory response. Key cytokines: IL-4, IL-5, and IL-13 stimulate the production of eotaxin-3
More informationASTHMA RESOURCE PACK Section 3. Chronic Cough Guidelines
ASTHMA RESOURCE PACK Section 3 Chronic Cough Guidelines NHS Fife Guidelines for the Management of Chronic Cough in Adults In this section: 1. Introduction 2. Scope Guidelines for Management of Chronic
More informationAssessment of reflux symptom severity: methodological options and their attributes
iv28 Assessment of reflux symptom severity: methodological options and their attributes P Bytzer... Despite major advances in our understanding of reflux disease, the management of this disorder still
More informationInternational Journal of Medical Science and Education pissn eissn
COMPARISON OF MONTELUKAST AND KETOTIFEN AS ADD ON THERAPY IN MODERATE AND SEVERE PERSISTENT BRONCHIAL ASTHMA Dr. Gaurav Chhabra 1, Dr. Shubhakaran Sharma 2* Original research article 1,2 Associate professor,
More informationINFLUENCE OF ANTISECRETORY THERAPY ON THE COURSE OF BRONCHIAL
INFLUENCE OF ANTISECRETORY THERAPY ON THE COURSE OF BRONCHIAL ASTHMA COMBINED WITH GASTROESOPHAGEAL REFLUX DISEASE Z. Z. Saatov, E. H. Dusmuhamedova, G. N. Sobirova Republican specialized scientific and
More informationPrevalence of Bronchial Asthma in Patients with Endoscopically-Documented Esophagitis
94 Annals of Clinical & Laboratory Science, vol. 34, no. 1, 2004 Prevalence of Bronchial Asthma in Patients with Endoscopically-Documented Esophagitis G. Riccioni, 1 R. Della Vecchia, 2 V. Menna, 1 C.
More informationEffective Health Care
Effective Health Care Comparative Effectiveness of Management Strategies for Gastroesophageal Reflux Disease Executive Summary Background Gastroesophageal reflux disease (GERD), defined as weekly heartburn
More informationTreatment Strategy for Standard-Dose Proton Pump Inhibitor-Resistant Reflux Esophagitis
Review Treatment Strategy for Standard-Dose Proton Pump Inhibitor-Resistant Reflux Esophagitis Katsuhiko Iwakiri Department of Gastroenterology, Nippon Medical School, Graduate School of Medicine, Tokyo,
More informationMedical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease (Review)
Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease (Review) Donnellan C, Sharma N, Preston C, Moayyedi P This is a reprint of a Cochrane review,
More informationSYNOPSIS. Co-ordinating investigator Not applicable. Study centre(s) This study was conducted in Japan (57 centres).
Drug product: Symbicort Turbuhaler Drug substance(s): ST (Symbicort Turbuhaler ) Edition No.: 1.0 Study code: D5890C00010 Date: 15 March 2007 SYNOPSIS An 8-week, randomised, double blind, parallel-group,
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationProton Pump Inhibitors (PPIs) (Sherwood Employer Group)
Proton Pump Inhibitors (PPIs) (Sherwood Employer Group) BCBSKS will review Prior Authorization requests Prior Authorization Form: https://www.bcbsks.com/customerservice/forms/pdf/priorauth-6058ks-st-ippi.pdf
More informationWhat s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university
What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent
More informationHigh use of maintenance therapy after triple therapy regimes in Ireland
High use of maintenance therapy after triple therapy regimes in Ireland K Bennett, H O Connor, M Barry, C O Morain, J Feely Department of Pharmacology & Therapeutics Department of Gastroenterology Trinity
More informationDisclosures. Heartburn and Barrett s Esophagus. Heartburn and Barrett s Esophagus. GERD is common in the U.S. None
Heartburn and Barrett s Esophagus None Disclosures Christian Mathy, MD University of California, San Francisco 2015 Heartburn and Barrett s Esophagus Heartburn and GERD GERD therapy Extraesophageal GERD
More informationDrug Class Review on Proton Pump Inhibitors
Drug Class Review on Proton Pump Inhibitors Evidence Tables July 2006 Original Report Date: November 2002 Update 1 Report Date: April 2003 Update 2 Report Date: April 2004 Update 3 Report Date: May 2005
More informationPutting Chronic Heartburn On Ice
Putting Chronic Heartburn On Ice Over the years, gastroesophageal reflux disease has proven to be one of the most common complaints facing family physicians. With quicker diagnosis, this pesky ailment
More informationSUMMARY INTRODUCTION. Aliment Pharmacol Ther 2000; 14: 1595±1603. Accepted for publication 14 August 2000
Aliment Pharmacol Ther 2000; 14: 1595±1603. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal re ux disease (GERD)
More informationPeptic ulcer disease Disorders of the esophagus
Peptic ulcer disease Disorders of the esophagus Peptic ulcer disease Burning epigastric pain Exacerbated by fasting Improved with meals Ulcer: disruption of mucosal integrity >5 mm in size, with depth
More informationMany patients with gastroesophageal reflux
... HEALTH ECONOMICS... Efficacy and Cost Effectiveness of Lansoprazole Versus Omeprazole in Maintenance Treatment of Symptomatic Gastroesophageal Reflux Disease Eva Vivian, PharmD; Anthony Morreale, PharmD,
More informationSymptomatic outcome following laparoscopic anterior 180 partial fundoplication: Our initial experience
International Journal of Medicine and Medical Sciences Vol. 2(4), pp. 128-132, April 2010 Available online http://www.academicjournals.org/ijmms ISSN 2006-9723 2010 Academic Journals Full Length Research
More information11/15/2017. Highgate Private Hospital (Royal Free London NHS Foundation Trust) Causes of chronic cough
A whistle stop of Chronic Cough For 10min consultations.. Dr Dean Creer Consultant Chest Physician (MBChB, FRCP) Highgate Private Hospital (Royal Free London NHS Foundation Trust) E: drcreer.pa@gmail.com(secretary)
More informationACG Clinical Guideline: Diagnosis and Management of Gastroesophageal Reflux Disease
ACG Clinical Guideline: Diagnosis and Management of Gastroesophageal Reflux Disease Philip O. Katz MD 1, Lauren B. Gerson MD, MSc 2 and Marcelo F. Vela MD, MSCR 3 1 Division of Gastroenterology, Einstein
More informationChronic cough and gastro-oesophageal reflux: a double-blind placebo-controlled study with omeprazole
Eur Respir J 2000; 16: 633±638 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 2000 European Respiratory Journal ISSN 0903-1936 Chronic cough and gastro-oesophageal reflux: a double-blind
More informationIs Proton Pump Inhibitor Therapy for Reflux Esophagitis Sufficient?: A Large Real-world Survey of Japanese Patients
ORIGINAL ARTICLE Is Proton Pump Inhibitor Therapy for Reflux Esophagitis Sufficient?: A Large Real-world Survey of Japanese Patients Kazuhide Higuchi 1, Takashi Joh 2, Koji Nakada 3 and Ken Haruma 4 Abstract
More informationGASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali
GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers
More informationFrequency of nocturnal symptoms in asthmatic children attending a hospital out-patient clinic
Eur Respir J, 1995, 8, 2076 2080 DOI: 10.1183/09031936.95.08122076 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1995 European Respiratory Journal ISSN 0903-1936 Frequency of nocturnal
More informationSYNOPSIS A two-stage randomized, open-label, parallel group, phase III, multicenter, 7-month study to assess the efficacy and safety of SYMBICORT
Drug product: Drug substance(s): Edition No.: Study code: SYMBICORT pmdi 160/4.5 g Budesonide/formoterol D5896C00005 Date: 8 May 2006 SYNOPSIS A two-stage randomized, open-label, parallel group, phase
More informationGASTROESOPHAGEAL REFLUX DISEASE. William M. Brady
Drugs of Today 1998, 34(1): 25-30 Copyright PROUS SCIENCE GASTROESOPHAGEAL REFLUX DISEASE William M. Brady Section of General Internal Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania,
More informationRisk Factors for Helicobacter pylori Infection and Endoscopic Reflux Esophagitis in Healthy Young Japanese Volunteers
doi: 10.2169/internalmedicine.8669-16 Intern Med 56: 2979-2983, 2017 http://internmed.jp ORIGINAL ARTICLE Risk Factors for Helicobacter pylori Infection and Endoscopic Reflux in Healthy Young Japanese
More informationGASTROESOPHAGEAL reflux
ORIGINAL INVESTIGATION Lansoprazole Compared With Ranitidine for the Treatment of Nonerosive Gastroesophageal Reflux Disease Joel E. Richter, MD; Donald R. Campbell, MD; Peter J. Kahrilas, MD; Bidan Huang,
More informationRESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
More informationRefractory GERD: What s a Gastroenterologist To Do?
Refractory GERD: What s a Gastroenterologist To Do? Philip O. Katz, MD, FACG Chairman, Division of Gastroenterology Einstein Medical Center Clinical Professor of Medicine Jefferson Medical College Philadelphia,
More informationBIOMEDICAL REPORTS 6: , 2017
BIOMEDICAL REPORTS 6: 175-180, 2017 Efficacy of a potassium competitive acid blocker for improving symptoms in patients with reflux esophagitis, non erosive reflux disease, and functional dyspepsia DAISUKE
More informationGERD DIAGNOSIS & TREATMENT DISCLOSURES 4/18/2018
GERD DIAGNOSIS & TREATMENT Subhash Chandra MBBS Assistant Professor CHI Health Clinic Gastroenterology Creighton University, School of Medicine April 28, 2018 DISCLOSURES None 1 OBJECTIVES Review update
More informationG. Boyd on behalf of a UK Study group
Eur Respir J, 1995, 8, 1494 1498 DOI: 10.1183/09031936.95.08091494 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1995 European Respiratory Journal ISSN 0903-1936 Salmeterol xinafoate in
More informationInternational co-ordinating investigator Dr Dencho Osmanliev, St Sofia, Pulmonary Dept, 19 D Nestorov Str, Sofia, 1431, Bulgaria.
Drug product: SYNOPSIS Drug substance(s): Budesonide/formoterol Document No.: SD-039-CR-0681 Referring to part Edition No.: 1 of the dossier Study code: SD-039-0681 Date: 24 Oktober, 2003 (For national
More informationProton Pump Inhibitors Drug Class Prior Authorization Protocol
Proton Pump Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review
More informationSUMMARY INTRODUCTION. Accepted for publication 4 June 2004
Aliment Pharmacol Ther 24; 2: 899 97. doi: 1.1111/j.1365-236.24.2176.x Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way
More informationIs CPAP helpful in severe Asthma?
Is CPAP helpful in severe Asthma? P RAP UN KI TTIVORAVITKUL, M.D. PULMONARY AND CRITICAL CARE DIVISION DEPARTMENT OF MEDICINE, PHRAMONGKUTKLAO HOSPITAL Outlines o Obstructive sleep apnea syndrome (OSAS)
More informationSUMMARY THIS IS A PRINTED COPY OF AN ELECTRONIC DOCUMENT. PLEASE CHECK ITS VALIDITY BEFORE USE.
i SUMMARY ZENECA PHARMACEUTICALS FINISHED PRODUCT: ACTIVE INGREDIENT: ACCOLATE zafirlukast (ZD9188) Trial title (number): A Dose-ranging, Safety and Efficacy Trial with Zafirlukast (ACCOLATE ) in the Treatment
More informationBUDESONIDE AND FORMOTEROL (SYMBICORT ): Α A REVIEW
Volume 23, Issue 3 December 2007 BUDESONIDE AND FORMOTEROL (SYMBICORT ): A REVIEW Donna L. Smith, Pharm. D. Candidate More than 22 million people in the United States have asthma according to the Centers
More informationDrug Class Monograph
Drug Class Monograph Class: Proton Pump Inhibitors Drugs: Aciphex Sprinkle (rabeprazole), Dexilant (dexlansoprazole), Lansoprazole, Nexium (esomeprazole capsule, esomeprazole granules), Omeprazole, Pantoprazole,
More informationEvaluation and Management of Refractory Asthma
Evaluation and Management of Refractory Asthma Non-Pharmacological Treatments: Comorbidities & Bronchial Thermoplasty Diego J Maselli, MD, FCCP Assistant Professor of Medicine Division of Pulmonary Diseases
More informationInternational Journal of Medical Research & Health Sciences
International Journal of Medical Research & Health Sciences www.ijmrhs.com Volume 2 Issue 3 July - Sep Coden: IJMRHS Copyright @2013 ISSN: 2319-5886 Received: 23 th May 2013 Revised: 24 th Jun 2013 Accepted:
More informationORIGINAL ARTICLE. Abstract
ORIGINAL ARTICLE Characteristics of Refractory Gastroesophageal Reflux Disease (GERD) Symptoms Is Switching Proton Pump Inhibitors Based on the Patient s CYP2C19 Genotype an Effective Management Strategy?
More informationDrug Class Review Proton Pump Inhibitors
Drug Class Review Proton Pump Inhibitors Evidence Tables April 2009 Update 4: May 2006 Update 3: May 2005 Update 2: April 2004 Update 1: April 2003 Original Report: November 2002 The literature on this
More informationReview article: alternative approaches to the long-term management of GERD
Aliment Pharmacol Ther 2005; 22 (Suppl. 3): 39 44. Review article: alternative approaches to the long-term management of GERD M. B. FENNERTY Division of Gastroenterology, Oregon Health and Science University,
More informationScottish Medicines Consortium
Scottish Medicines Consortium budesonide/formoterol 100/6, 200/6 turbohaler (Symbicort SMART ) No. (362/07) Astra Zeneca UK Limited 9 March 2007 (Issued May 2007) The Scottish Medicines Consortium (SMC)
More information